MONTREAL, March 10, 2020 /CNW Telbec/ - The topical analgesic Pliaglis has long been awaited by many doctors and dermatologists in Canada because it offers patients an effective alternative to traditional analgesic creams for relieving pain prior to superficial dermatological procedures. Effective, simple and easy-to-use because it can easily be removed after 20 minutes, Pliaglis delivers a unique concentration of topical anaesthetic agents to the market. In fact, it contains a higher concentration of lidocaine than other analgesic creams sold in Canada. It also contains tetracaine, a powerful analgesic commonly used in cosmetic procedures, such as laser therapy, intense pulsed light (IPL) therapy or electrolysis. When used at the recommended dosage, the product is safe, and it is the only formula with this maximum allowable concentration to be approved by Heath Canada. Now available by prescription in Canada, Pliaglis is the only topical analgesic approved by Health Canada and by the U.S. Food and Drug Administration (FDA).
Pliaglis delivers powerful pain-killing action and its unique application method – it is a peel-off cream1 which dries to form a pliable layer within 20 minutes – allows patients to benefit from optimum local anaesthesia for pain-free injections of collagen or dermal filler, hair removal, tattoo removal, laser therapy, resurfacing and other procedures.
Not only has the effectiveness and the high tolerance of Pliaglis been demonstrated in clinical trials2, but the product has been used successfully in medical practices in Europe, South America and the United States.
74% of patients considering a cosmetic procedure were concerned about pain3 Pliaglis is different from the other analgesic creams that patients are required to apply before a procedure. In addition to the recognized pain-killing action of lidocaine, the high concentration of tetracaine (7%) in Pliaglis gives patients and health professionals peace of mind about the efficacy of its numbing action, which lasts up to nine hours post-procedure.
The innovative application method improves the treatment experience Pliaglis is applied by the health professional prior to the procedure using a spatula at a dosage of approximately 1.3g per square centimetre of skin. Thanks to "Peel" technology, the cream dries to form a pliable layer which acts like a medicinal patch. The lidocaine and tetracaine contained in Pliaglis are released to the pain receptors and nerve endings of the epidermis for optimal anaesthetic effect. The layer is peeled off after 30 minutes (in most cases) and the skin is then ready for the procedure.
Pliaglis has been certified safe by Health Canada and the product is sold only by prescription. Pliaglis is sold in a 30g tube at a recommended price of $50 (minimum of three tubes per order).
About Crescita Therapeutics Inc.
Crescita (TSX: CTX) is a publicly traded, Canadian commercial dermatology company with a manufacturing facility and a portfolio of non-prescription skincare products and prescription drugs for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. For more information, please see www.crescitatherapeutics.com.
Pliaglis monograph. CRESCITA Therapeutics Inc., December 4, 2012. Other topical anaesthetics currently on the market contain lidocaine and tetracaine in concentrations of 5%.
Four clinical trials in which adults were treated either with Pliaglis or a placebo.
Sarkany, M., Limitations of currently used topical anaesthetics in daily practice. Poster presented to the IMCAS World Congress 2012 as part of the 14th International Master Course on Ageing Skin, Paris, France, from January 26 to 29, 2012.